Zai Lab (MEX:ZLAB N) Capex-to-Operating-Cash-Flow: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ZLAB N Zai Lab Ltd MEX:ZLAB N
81 GF Score
Price MXN810.00
GF Value MXN952.21
! 8 Warning Signs
View Full Analysis

What is Zai Lab Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Zai Lab's Capital Expenditure for the three months ended in Jun. 2026 was MXN-21.90 Mil. Its Cash Flow from Operations for the three months ended in Jun. 2026 was MXN-1,139.52 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Zai Lab  (MEX:ZLAB N) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Zai Lab Capex-to-Operating-Cash-Flow Related Terms


Zai Lab Capex-to-Operating-Cash-Flow Historical Data

* Premium members only.

The historical data trend for Zai Lab's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zai Lab Capex-to-Operating-Cash-Flow Chart

Zai Lab Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zai Lab Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MEX:ZLAB N vs ALMS, ARQT, BEAM: Capex-to-Operating-Cash-Flow Comparison

For the Biotechnology subindustry, Zai Lab's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zai Lab Capex-to-Operating-Cash-Flow vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Zai Lab's Capex-to-Operating-Cash-Flow falls into.


MEX:ZLAB N
81GF Score
Zai Lab Ltd MEX:ZLAB N
Capex-to-Operating-Cash-Flow is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zai Lab Capex-to-Operating-Cash-Flow Calculation

Zai Lab's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2025 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-257.74576605488) / -2895.2045826616
=N/A

Zai Lab's Capex-to-Operating-Cash-Flow for the quarter that ended in Jun. 2026 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-21.900192724196) / -1139.5188962186
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Zai Lab (MEX:ZLAB N) Overvalued in 2026?

Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued. The current stock price of MXN810.00 is trading 14.9% below its estimated GF Value™ of MXN952.21.

Key valuation signals for MEX:ZLAB N:

  • Capex-to-Operating-Cash-Flow:
  • GF Value™: MXN952.21 vs. price of MXN810.00 (14.9% below fair value)
  • GF Score™: 81/100 with 8 warning signs

No single metric tells the full story. See the MEX:ZLAB N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zai Lab Business Description

Address 899 Halei Road, Building B, Pudong, Shanghai, CHN, 201203
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
81GF Score

Get the complete analysis for MEX:ZLAB N

Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN810.00
Price
MXN952.21
GF Value